Ultra high-pressure liquid chromatographic assay of moxifloxacin in rabbit aqueous humor after topical instillation of moxifloxacin nanoparticles.
The present report describes a rapid and sensitive ultra high-pressure liquid chromatography (UHPLC) method with UV detection to quantify moxifloxacin in rabbit aqueous humor. After deproteinisation with acetonitrile, gradient separation of moxifloxacin was achieved on a Waters Acquity BEH C18 (50mmx2.1mm, 1.7microm) column at 50 degrees C. The mobile phase consisted of 0.1% trifluoroacetic acid in water and acetonitrile at a flow rate of 0.4ml/min. Detection of moxifloxacin was done at 296nm. Method was found to be selective, linear (r=0.9997), accurate (recovery, 97.30-99.99%) and precise (RSD, <or=1.72%) in the selected concentration range of 10-1000ng/ml. Detection and quantitation limit of moxifloxacin in aqueous humor were 0.75 and 2.5ng/ml, respectively. The aqueous humor levels of moxifloxacin after single topical instillation in three formulations, i.e. moxifloxacin solution (Moxi-SOL), anionic nanoparticles (Moxi-ANP) and cationic nanoparticles (Moxi-CNP) were investigated. A fourfold increase in the relative bioavailability was observed with the Moxi-CNP (AUC(0-->t), 3.14microg h/ml) compared with Moxi-SOL (AUC(0-->t), 0.79microg h/ml) and Moxi-ANP (AUC(0-->t), 0.72microg h/ml) formulation. The results indicate that the cationic nanoparticle increases ocular bioavailability of moxifloxacin and prolong its residence time in the eye.
Jain
Gaurav K
GK
Department of Pharmaceutics, F/O Pharmacy, Hamdard University, Hamdard Nagar, New Delhi 110062, India. drgkjain@gmail.com
Jain
Nilu
N
Pathan
Shadab A
SA
Akhter
Sohail
S
Talegaonkar
Sushma
S
Chander
Prakash
P
Khar
Roop K
RK
Ahmad
Farhan J
FJ
D000287:Administration, Topical; D000818:Animals; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D001082:Aqueous Humor / Q000378:metabolism*; D019540:Area Under Curve; D001372:Aza Compounds / Q000008:administration & dosage / Q000493:pharmacokinetics*; D001682:Biological Availability; D002138:Calibration; D002626:Chemistry, Pharmaceutical; D002851:Chromatography, High Pressure Liquid / Q000592:standards; D004355:Drug Stability; D024841:Fluoroquinolones; D000077266:Moxifloxacin; D053758:Nanoparticles; D011804:Quinolines / Q000008:administration & dosage / Q000493:pharmacokinetics*; D011817:Rabbits; D012015:Reference Standards; D015203:Reproducibility of Results; D013056:Spectrophotometry, Ultraviolet
D000890:Anti-Infective Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D000077266:Moxifloxacin